Black Diamond Therapeutics, Inc.

4 articles with Black Diamond Therapeutics, Inc.

• Black Diamond Therapeutics Appoints Industry Veteran as Chief Operating Officer and General Counsel

  5/29/2019

  Team also strengthened with key hires in preclinical and clinical development, clinical operations, and finance to drive company's lead program into the clinic in 2020 and advance its pipeline and MAP platform

• Black Diamond Therapeutics Presents Data From its Program Targeting Oncogenic Allosteric Mutations in EGFR for Glioblastoma as Late Breaker at the American Association for Cancer Research (AACR) Annual Meeting

  3/29/2019

  Black Diamond Therapeutics, Inc. announced that data from its first-in-class program targeting a group of epidermal growth factor receptor allosteric mutants that drive glioblastoma multiforme will be presented at the American Association for Cancer Research Annual Meeting 2019.

• Black Diamond Therapeutics Closes $85 Million Series B Financing

  1/10/2019

  Next-wave precision oncology company poised to advance multiple products into clinical development

• Versant Ventures Launches Black Diamond Therapeutics

  12/11/2018

  Next-wave precision oncology company emerges from Versant’s Ridgeline Discovery Engine